Algisyl-LVR® to be the subject of two scientific presentations at the 9th Conference on Cell Therapy for Cardiovascular Disease in New York City
Laguna Hills, CA, January 8, 2014 – Algisyl-LVR®, an implantable hydrogel to treat advanced heart failure patients who have a dilated left ventricle, will be the subject of two scientific presentations at the 9th Conference on Cell Therapy for Cardiovascular Disease sponsored by the Cardiovascular Research Foundation in New York City on January 22-24, 2014.
Authored by Jay W. Schneider, MD, Ph.D., Assistant Professor at the Department of Internal Medicine- Cardiology at the University of Texas Southwestern Medical Center at Dallas, the first presentation describes ground-breaking research to identify the molecular and genomic events that contribute to the healing response when Algisyl-LVR® is delivered to the heart muscle. It is entitled “Mechanistic Insights from Alginate in Mouse Heart: Stealth Myocardial Engraftment and Molecular Signaling to the Cardiac Genome.”
Authored by Randall J. Lee, MD, Ph.D., Professor of Medicine and cardiologist-electrophysiologist at University of California San Francisco, the second presentation will focus on the findings from the clinical studies carried out with Algisyl-LVR® to date. It is entitled “Alginate Application in Heart Failure Patients.”
The 9th Conference on Cell Therapy for Cardiovascular Disease is directed by Warren Sherman, MD, Director of Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy at Columbia University Medical Center. The conference constitutes the premier meeting dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease.
Classified by the U.S. Food and Drug Administration as a medical device, Algisyl-LVR is intended to reverse HF progression in patients who have an enlarged left ventricle. The product consists of a proprietary hydrogel that is injected directly into strategic areas of the dilated left ventricle muscle in a surgical procedure lasting approximately 75 minutes. Performing the function of a prosthetic scaffold, the hydrogel acts immediately and does not undergo long-term degradation. Extensive preclinical studies have shown Algisyl-LVR decreases cardiac wall tension, while it improves heart muscle contractility and oxygen uptake, leading to a decrease in ventricle stress and to a marked cardiomechanic improvement. The safety and efficacy of Algisyl-LVR® are being evaluated in clinical trials in Europe and Australia. The product is not available for sale.
Advanced Heart Failure:
Advanced HF represents a significant and growing epidemic healthcare burden in all developed countries. Of the more than 12 million patients affected in the North America and in Western Europe, about a third have significant limitations of physical activity while half die of heart failure within five years of diagnosis. A wide number of patients whose heart muscle is initially damaged by infarcts, hypertension, valve disease, or other processes lose the ability to pump blood efficiently to the body. To overcome the initial damage, the heart muscle works under increased stress without an opportunity to recover. Eventually, the muscle of the left ventricle begins to stretch out and the muscle cells lose the ability to contract normally. The therapeutic options for many of these patients who do not respond to drug and device therapies are limited and can be extremely complex and costly.
LoneStar Heart Inc.:
LoneStar Heart, Inc., based in Laguna Hills, Calif., is developing cardiac restorative therapies for patients with heart failure that harness the heart's ability to repair itself. Based on its integrated cardiomechanical and biomolecular technologies, the privately held company is advancing a broad portfolio of products to restore the failing heart's structure and function in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center, and a global network of leading clinicians. These products include Algisyl-LVR, cardiac stem-cell modulators, and cellular and genetic therapies delivered as stand-alone treatments, or in combination with the company's proprietary biopolymer matrix system.